Skystar Bio Pharmaceutical Company Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2013; Reiterates Revenue Guidance for the Year 2013
The company reiterated fiscal 2013 revenue guidance range of $40 million to $45 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% |
|
-.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 0 | |
+25.83% | 47.96B | |
+44.76% | 41.47B | |
+0.69% | 42.45B | |
+30.52% | 31.6B | |
+22.30% | 28.63B | |
-6.35% | 28.03B | |
+49.25% | 14.56B | |
+49.18% | 14.14B | |
+3.45% | 12.58B |